1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given concomitantly with cytosine arabinoside (NSC-63878) in the treatment of cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000633:toxicity; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D014508:Urea / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D003561:Cytarabine; D014508:Urea